# A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

> **NCT06769113** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 102 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** HLX43

## Key facts

- **NCT ID:** NCT06769113
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-26
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-06-05
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769113, "A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT06769113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*